Holly joined Dehns as a Trainee Patent Attorney in the Biotechnology Group in June 2022. Before starting at Dehns, Holly completed her PhD at the University of Edinburgh. Holly’s research focused on studying the resolution of inflammation in skin wound healing with a particular focus on aberrant inflammation and pro-resolving pathways in acute and chronic wounds.
Prior to her PhD, Holly graduated from the University of Aberdeen with a BSc in Pharmacology. During her undergraduate degree, Holly conducted several laboratory projects including researching whether cannabinoid receptor ligands were able to improve insulin signalling in hepatic tissue and optimising microfluidic devices for co-culturing cells for motor neurone disease research.
Holly has experience working with a variety of clients including solo inventors, small/medium-sized enterprises and larger companies.
She has gained experience in patent prosecution in all key IP jurisdictions including the EPO, the UK, the US, Canada, China, the Republic of Korea and Japan. Holly has also gained experience in all aspects of patent drafting in collaboration with partners.
Since joining the firm, Holly has worked in many technical areas of biochemistry/biotechnology. Particular areas include antibody and cell-based therapies, immunology, new medical uses of known compounds, diagnostic assays, new pharmaceuticals and vaccines.
PGCert Intellectual Property Law, Queen Mary University of London, 2023
Student Member of the Chartered Institute of Patent Attorneys (CIPA)
PhD, University of Edinburgh, 2021
BSc (Hons) Pharmacology, University of Aberdeen, 2017